Key insights
- Merck KGaA initiated Phase 3 trials for enpatoran, a lupus skin treatment. Despite clinical progress, Merck's stock is down 11% YTD and near its 52-week low. InvestingPro data suggests the stock is undervalued. While positive for Merck, the news has a limited bearish influence on the broader US equity market due to the stock's decline despite positive developments.
DARMSTADT, Germany - Merck KGaA, Darmstadt, Germany dosed the first patient in its Phase 3 ELOWEN program evaluating enpatoran for lupus patients with active skin manifestations, according to a press release statement. The $55.7 billion pharmaceutical company maintains a prominent position in the industry with a gross profit margin of 59%, according to InvestingPro data.
The ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218) studies are global randomized, double-blind, placebo-controlled trials testing enpatoran taken twice daily versus placebo, on top of standard care. The program will be conducted at 266 sites across 26 countries, with each study recruiting approximately 200 participants. The primary endpoint measures change in CLASI-A from baseline.
Enpatoran is an oral selective toll-like receptor 7/8 inhibitor designed to modulate pathways central to lupus-related inflammation. The compound is investigational and has not been approved for any use.
Despite the promising clinical progress, Merck’s stock has declined 11% year-to-date and currently trades near its 52-week low. InvestingPro analysis suggests the stock appears undervalued, with subscribers accessing comprehensive Fair Value estimates and over 8 additional ProTips for MKKGY.
"People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations," said David Weinreich, Global Head of R&D at Merck KGaA, Darmstadt, Germany.
Up to 85% of lupus patients experience skin manifestations, which are among the most visible signs of disease. Skin symptoms are the first sign of disease in 29% of cases.
The ELOWEN program builds on Phase 2 findings where enpatoran demonstrated improvements in patients with active cutaneous manifestations, according to principal investigator Professor Eric Morand.
Lupus is a chronic autoimmune disease that can affect multiple organ systems including the skin, joints, kidneys and central nervous system. The disease disproportionately affects women and people of color.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.